IP Library › Granted Patent US 12,397,017
Granted Patent B2
US 12,397,017 · App. 17/986,092 · Granted Aug 26, 2025

Fortified nutritional lubricating drops for dry eye disease

Inventor: Kenneth Reed (Brentwood, TN)
Assignee: PLATFORM OPHTHALMIC INNOVATIONS, LLC
A61K31/79A61K9/0048A61K31/198A61K31/728A61K47/02A61K47/12A61K47/18A61K47/22A61K47/26A61K47/32A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,017
App. No.
17/986,092
Granted
Aug 26, 2025
Kind
B2
Abstract

The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature. The total nutritional approach uses metabolically important tear fluid amino acids, vitamins, natural antioxidants such as ferulic acid, and both fatty acids/triglycerides and sugar molecules as energy sources. The invention results in both improved eye health and improved dry eye patient comfort.

Claims (136)

1. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent comprising povidone with a concentration in the range of between about 1% and about 3% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w) and combinations thereof;

c. pecan nut oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof at a concentration of about 0.1% (w/w);

e. one or more antioxidants selected from the group consisting of ascorbic acid or salts thereof, ascorbyl palmitate, Vitamin E, tocopherol, ferulic acid, and trisodium citrate, and combinations thereof;

f. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

g. carbomer copolymer type B at a concentration of about 0.005% (w/w);

h. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

i. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

j. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

2. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent comprising povidone with a concentration in the range of between about 1% and about 3% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w) and combinations thereof;

c. perilla seed oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof at a concentration of about 0.1% (w/w);

e. one or more antioxidants selected from the group consisting of ascorbic acid or salts thereof, ascorbyl palmitate, Vitamin E, tocopherol, ferulic acid, and trisodium citrate, and combinations thereof;

f. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

g. carbomer copolymer type B at a concentration of about 0.005% (w/w);

h. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

i. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

j. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

3. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent selected from the group consisting of povidone at a concentration of about 1.25% (w/w) and povidone at a concentration of about 1.5% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w), and the surfactant further comprising poloxamer 407 at a concentration of about 2% (w/w) and carbomer copolymer type B at a concentration of about 0.005% (w/w);

c. anchovy oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof;

e. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

f. tocopherol at a concentration of about 0.002% (w/w), ascorbic acid at a concentration of about 0.1% (w/w), trisodium citrate at a concentration up to about 3% (w/w), and ferulic acid at a concentration of about 0.02% (w/w);

g. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

h. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

i. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

4. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent selected from the group consisting of povidone at a concentration of about 1.25% (w/w) and povidone at a concentration of about 1.5% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w), and the surfactant further comprising poloxamer 407 at a concentration of about 2% (w/w) and carbomer copolymer type B at a concentration of about 0.005% (w/w);

c. chia seed oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof;

e. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

f. tocopherol at a concentration of about 0.002% (w/w), ascorbic acid at a concentration of about 0.1% (w/w), trisodium citrate at a concentration up to about 3% (w/w), and ferulic acid at a concentration of about 0.02% (w/w);

g. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

h. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

i. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

5. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent selected from the group consisting of povidone at a concentration of about 1.25% (w/w) and povidone at a concentration of about 1.5% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w), and the surfactant further comprising poloxamer 407 at a concentration of about 2% (w/w) and carbomer copolymer type B at a concentration of about 0.005% (w/w);

c. pecan nut oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof;

e. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

f. tocopherol at a concentration of about 0.002% (w/w), ascorbic acid at a concentration of about 0.1% (w/w), trisodium citrate at a concentration up to about 3% (w/w), and ferulic acid at a concentration of about 0.02% (w/w);

g. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

h. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

i. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

6. An ophthalmic pharmaceutical formulation, comprising:

a. a demulcent selected from the group consisting of povidone at a concentration of about 1.25% (w/w) and povidone at a concentration of about 1.5% (w/w);

b. a surfactant selected from the group consisting of polyoxyl 40 hydrogenated castor oil at a concentration of about 1% (w/w) and polyoxyl 35 castor oil at a concentration of about 4% (w/w), and the surfactant further comprising poloxamer 407 at a concentration of about 2% (w/w) and carbomer copolymer type B at a concentration of about 0.005% (w/w);

c. perilla seed oil at a concentration of about 0.15% (w/w);

d. hyaluronic acid or a salt thereof;

e. a tonicity agent selected from the group consisting of mannitol, sorbitol, and dextrose, and combinations thereof, in a total amount of up to about 5% (w/w);

f. tocopherol at a concentration of about 0.002% (w/w), ascorbic acid at a concentration of about 0.1% (w/w), trisodium citrate at a concentration up to about 3% (w/w), and ferulic acid at a concentration of about 0.02% (w/w);

g. one or more amino acids selected from the group consisting of glutamic acid, serine, phenylalanine, aspartic acid, threonine, leucine, lysine, and isoleucine, and combinations thereof, in a total amount of amino acids up to about 6% (w/w);

h. a pH adjusting agent selected from the group consisting of tromethamine and hydrochloric acid, and combinations thereof, such that the ophthalmic pharmaceutical formulation pH is at a level in the range from about 6.8 to about 7.8; and

i. water;

wherein the ophthalmic pharmaceutical formulation is preservative-free.

7. An ophthalmic pharmaceutical formulation, comprising:

a. castor oil at a concentration of about 0.15% (w/w);

b. polyoxyl 35 castor oil at a concentration of about 4% (w/w);

c. poloxamer 407 at a concentration of about 2% (w/w);

d. carbomer copolymer type B at a concentration of about 0.005% (w/w);

e. povidone at a concentration of about 1.25% (w/w);

f. sodium hyaluronate at a concentration of about 0.1% (w/w);

g. sorbitol at a concentration of about 4.5%; and

h. water.

8. An ophthalmic pharmaceutical formulation, comprising:

a. tocopherol at a concentration of about 0.002% (w/w);

b. castor oil at a concentration of about 0.15% (w/w);

c. polyoxyl 35 castor oil at a concentration of about 4% (w/w);

d. poloxamer 407 at a concentration of about 2% (w/w);

e. carbomer copolymer type B at a concentration of about 0.005% (w/w);

f. povidone at a concentration of about 1.25%;

g. ascorbic acid at a concentration of about 0.1%;

h. trisodium citrate at a concentration of about 0.45%;

i. sodium hyaluronate at a concentration of about 0.1% (w/w);

j. sorbitol at a concentration of about 3.3% (w/w); and

k. water.

9. An ophthalmic pharmaceutical formulation, comprising:

a. castor oil at a concentration of about 0.15% (w/w);

b. polyoxyl 40 castor oil at a concentration of about 1% (w/w);

c. poloxamer 407 at a concentration of about 2% (w/w);

d. carbomer copolymer type B at a concentration of about 0.005% (w/w);

e. povidone at a concentration of about 1.25% (w/w);

f. ascorbic acid at a concentration of about 0.03% (w/w);

g. trisodium citrate at a concentration of about 0.55% (w/w);

h. sodium hyaluronate at a concentration of about 0.1% (w/w);

i. glutamic acid at a concentration of about 0.084% (w/w);

j. serine at a concentration of about 0.061% (w/w);

k. phenylalanine at a concentration of about 0.037% (w/w);

l. aspartic acid at a concentration of about 0.03% (w/w);

m. threonine at a concentration of about 0.028% (w/w);

n. leucine at a concentration of about 0.022% (w/w);

o. lysine at a concentration of about 0.14% (w/w);

p. dextrose at a concentration of about 3% (w/w); and

q. water.

10. An ophthalmic pharmaceutical formulation, comprising:

a. castor oil at a concentration of about 0.15% (w/w);

b. polyoxyl 40 castor oil at a concentration of about 1% (w/w);

c. poloxamer 407 at a concentration of about 2% (w/w);

d. carbomer copolymer type B at a concentration of about 0.005% (w/w);

e. povidone at a concentration of about 1.25% (w/w);

f. ascorbic acid at a concentration of about 0.03% (w/w);

g. trisodium citrate at a concentration of about 0.55% (w/w);

h. sodium hyaluronate at a concentration of about 0.1% (w/w);

i. glutamic acid at a concentration of about 0.084% (w/w);

j. serine at a concentration of about 0.061% (w/w);

k. phenylalanine at a concentration of about 0.037% (w/w);

l. aspartic acid at a concentration of about 0.03% (w/w);

m. threonine at a concentration of about 0.028% (w/w);

n. leucine at a concentration of about 0.022% (w/w);

o. lysine at a concentration of about 0.14% (w/w);

p. trehalose at a concentration of about 3% (w/w);

q. dextrose at a concentration of about 1% (w/w); and

r. water.

11. The ophthalmic pharmaceutical formulation of claim 1 , further comprising lanolin.

12. The ophthalmic pharmaceutical formulation of claim 2 , further comprising lanolin.

13. The ophthalmic pharmaceutical formulation of claim 3 , further comprising lanolin.

14. The ophthalmic pharmaceutical formulation of claim 4 , further comprising lanolin.

15. The ophthalmic pharmaceutical formulation of claim 5 , further comprising lanolin.

16. The ophthalmic pharmaceutical formulation of claim 6 , further comprising lanolin.

17. The ophthalmic pharmaceutical formulation of claim 7 , further comprising lanolin.

18. The ophthalmic pharmaceutical formulation of claim 8 , further comprising lanolin.

19. The ophthalmic pharmaceutical formulation of claim 9 , further comprising lanolin.

20. The ophthalmic pharmaceutical formulation of claim 10 , further comprising lanolin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2022
From: REED, KENNETH
To: PLATFORM OPHTHALMIC INNOVATIONS, LLC,
Reel/Frame 061756/0157 →
Continuity (2)
Continuation In Part 17574288 · Jan 12, 2022
Related Publication 20240156859A1 · May 16, 2024
References Cited (43)
US 5981607A · Ding et al. · 1999 [cited by applicant]
US 7638142B2 · Krawitz · 2009 [cited by applicant]
US 8957048B2 · Vehige et al. · 2015 [cited by applicant]
US 8957110B2 · Aleo et al. · 2015 [cited by applicant]
US 9161905B2 · Korb et al. · 2015 [cited by applicant]
US 9480645B2 · Yu · 2016 [cited by applicant]
US 9668996B2 · O'Haimhirgin · 2017 [cited by applicant]
US 10279005B2 · Gore et al. · 2019 [cited by applicant]
US 10383889B2 · Belmonte et al. · 2019 [cited by applicant]
US 10660848B2 · Torres et al. · 2020 [cited by applicant]
US 20060251685A1 · Yu et al. · 2006 [cited by applicant]
US 20080050335A1 · Faour et al. · 2008 [cited by applicant]
US 20170105934A1 · Mizutare · 2017 [cited by examiner]
US 20230144779A1 · Singh Rawat · 2023 [cited by examiner]
WO WO2017182138A1 · 2017 [cited by examiner]
Aragona P, Rania L, Micali A, Puzzolo D. Nutrition and dry eye. Current Ophthalmology Reports. Jun. 2013;1(2):58-64. [cited by applicant]
Aragona P, Rania L, Roszkowska AM, Spinella R, Postorino E, Puzzolo D, Micali A. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome. Acta ophthalmologica. Sep. 2… [cited by applicant]
Bartollino S, Palazzo M, Semeraro F, Parolini B, Caruso C, Merolla F, Guerra G, Costagliola C. Effects of an antioxidant protective topical formulation on retinal tissue of UV-exposed rabbits. International ophthalmolog… [cited by applicant]
Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the O… [cited by applicant]
Brocker C, Thompson DC, Vasiliou V. The role of hyperosmotic stress in inflammation and disease. Biomolecular concepts. Aug. 1, 2012;3(4):345-64. [cited by applicant]
Butovich IA, Lipidomics of human meibomian gland secretions: chemistry, biophysics, and physiological role of meibomian lipids. Progress in lipid research. Jul. 1, 2011;50(3):278-301. [cited by applicant]
Butovich IA, Meibomian glands, meibum, and meibogenesis. Experimental eye research. Oct. 1, 2017;163:2-16. [cited by applicant]
Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive care medicine. May 2010;36(5):735-49. [cited by applicant]
Chen W, Zhang X, Li J, Wang Y, Chen Q, Hou C, Garrett Q. Efficacy of osmoprotectants on prevention and treatment of murine dry eye. Investigative ophthalmology & visual science. 2013. [cited by applicant]
Gilbard JP. Dry eye and the role of nutrition. Optom Today. Jun. 2004:34-41. [cited by applicant]
Jimenez-Arias D, Garcia-Machado FJ, Morales-Sierra S, Garcia-Garcia AL, Herrera AJ, Valdes F, Luis JC, Borges AA. A Beginner's Guide to Osmoprotection by Biostimulants. Plants. Feb. 2021;10(2):363. [cited by applicant]
Larmo P, Järvinen R, Laihia J, Loyttyniemi E, Maavirta L, Yang B, Kallio H, Sandberg-Lall M. Effects of a sea buckthorn oil spray emulsion on dry eye. Contact Lens and Anterior Eye. Aug. 1, 2019;42(4):428-33. [cited by applicant]
Modugno RL, Feuerman OM, La Gloria Valerio A, Scalora T, Salami E. A Novel Liposome-Based, Aminoacid-and Vitamin-Containing Tear Substitute in Patients with Evaporative Dry Eye Disease. A Pilot Prospective Study. J Comm… [cited by applicant]
O'Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in Dry Eye Disease Treatment. Curr Opin Ophthalmol. May 2019;30(3):166-78. [cited by applicant]
Perminaite K, Marksa M, Ivanauskas L, Ramanauskiene K. Preparation of Ophthalmic Microemulsions Containing Lithuanian Royal Jelly and Their Biopharmaceutical Evaluation. Processes. Apr. 2021;9(4):616. [cited by applicant]
Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database of Systematic Reviews. 2016(2). [cited by applicant]
Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Archives of ophthalmology. Feb. 1, 2008;126(2):219-25. [cited by applicant]
Salehi B, Quispe C, Sharifi-Rad J, Cruz-Martins N, Nigam M, Mishra AP, Konovalov DA, Orobinskaya V, Abu-Reidah IM, Zam W, Sharopov F. Phytosterols: from preclinical evidence to potential clinical applications. Frontiers… [cited by applicant]
Vizzarri FR, Palazzo MA, Bartollino SI, Casamassima DO, Parolini BA, Troiano PA, Caruso CI, Costagliola CI. Effects of an antioxidant protective topical formulation on eye exposed to ultraviolet-irradiation: a study in … [cited by applicant]
Worthley LI, Atkinson M. Nutrition in the critically ill patient: part II. Parenteral nutrition. [cited by applicant]
Widjaja-Adhi MA, Silvaroli JA, Chelstowska S, Trischman T, Bederman I, Sayegh R, Golczak M. Deficiency in Acyl-CoA: Wax Alcohol Acyltransferase 2 causes evaporative dry eye disease by abolishing biosynthesis of wax este… [cited by applicant]
Yao L, Hammond EG. Isolation and melting properties of branched-chain esters from lanolin. Journal of the American Oil Chemists' Society. Jun. 2006;83(6):547-52. [cited by applicant]
Zakaria El-Sayed HE, Mowafi S, El-Kheir A, El-Khatib EM. A Comprehensive Critique on Wool Grease Extraction, Properties and Applications. Egyptian Journal of Chemistry. Dec. 1, 2018;61(6):1151-9. [cited by applicant]
Gaia Favero, Enrico Moretti, Kristina Krajcikova, Vladimíra Tomeckova, Rita Rezzani. Evidence of Polyphenols Efficacy against Dry Eye Disease. Antioxidants 2021, 10, 190. [cited by applicant]
Kamila Zduńska Agnieszka Dana Anna Kolodziejczak Helena Rotsztejn. Antioxidant Properties of Ferulic Acid and Its Possible Application. Skin Pharmacol Physiol 2018;31:332-336. [cited by applicant]
Fu-Hsiung Lin, Jing-Yi Lin, Ravindra D. Gupta, Joshua A. Tournas, James A. Burch, M. Angelica Selim, Nancy A. Monteiro-Riviere, James M. Grichnik, Jan Zielinski, Sheldon R. Pinnell. Ferulic Acid Stabilizes a Solution of… [cited by applicant]
Shigeru Nakamura, Yuki Kimura, Daisuke Mori, Toshihiro Imada, Yusuke Izuta, Michiko Shibuya, Hisayo Sakaguchi, Erina Oonishi, Naoko Okada, Kenji Matsumoto, Kazuo Tsubota. Restoration of Tear Secretion in a Murine Dry Ey… [cited by applicant]
Provinal Technical Data Sheet EE-2021. [cited by applicant]